KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Other Non-Current Liabilities (2016 - 2025)

Historic Other Non-Current Liabilities for Supernus Pharmaceuticals (SUPN) over the last 15 years, with Q3 2025 value amounting to $11.4 million.

  • Supernus Pharmaceuticals' Other Non-Current Liabilities fell 7563.43% to $11.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.4 million, marking a year-over-year decrease of 7563.43%. This contributed to the annual value of $47.3 million for FY2024, which is 1143.12% down from last year.
  • According to the latest figures from Q3 2025, Supernus Pharmaceuticals' Other Non-Current Liabilities is $11.4 million, which was down 7563.43% from $7.8 million recorded in Q2 2025.
  • Supernus Pharmaceuticals' Other Non-Current Liabilities' 5-year high stood at $80.5 million during Q4 2021, with a 5-year trough of $7.8 million in Q2 2025.
  • Over the past 5 years, Supernus Pharmaceuticals' median Other Non-Current Liabilities value was $53.4 million (recorded in 2023), while the average stood at $49.9 million.
  • As far as peak fluctuations go, Supernus Pharmaceuticals' Other Non-Current Liabilities surged by 37418.66% in 2021, and later crashed by 8382.92% in 2025.
  • Over the past 5 years, Supernus Pharmaceuticals' Other Non-Current Liabilities (Quarter) stood at $80.5 million in 2021, then crashed by 31.7% to $55.0 million in 2022, then decreased by 2.76% to $53.4 million in 2023, then dropped by 11.43% to $47.3 million in 2024, then tumbled by 75.82% to $11.4 million in 2025.
  • Its Other Non-Current Liabilities stands at $11.4 million for Q3 2025, versus $7.8 million for Q2 2025 and $30.0 million for Q1 2025.